Interest of Eosinopenia to Predict In-hospital Mortality Among Elderly Patients
NCT ID: NCT04734431
Last Updated: 2021-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
224 participants
OBSERVATIONAL
2018-01-01
2020-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
decreased in eosinophil count (EC) is unspecific of a particular clinical picture and may support a systemic inflammation, whereas the deeper the eosinopenia is, the darker is the prognosis in ICU.
The duration of eosinopenia is not clearly documented, but it has been recently shown that EC tends to normalization, rapidly after appropriate and effective antimicrobial therapy in case of bacterial infection among adults patients hospitalized in a medicine ward. In the light of this findings, Terradas et al. described that EC returned back to normal between the day 2 or day 3 in survivors, indicating a potential interest as a predictive marker of the evolution among hospitalized patients.
To the best of our knowledge, no work has studied eosinopenia as a prognostic marker of mortality during bacterial infections in the elderly patients in a hospital setting. Our study aims to evaluate the prognosis value of the EC in a geriatric unit of tertiary care hospital.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Link Between Eosinopenia and Bacterial Infections in the Elderly Subject Hospitalized in Geriatrics
NCT04363138
Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department
NCT03467672
Impact of Age and Geriatric Co-morbidities on Lymphocyte Phenotype in Patients 70 Years of Age and Older
NCT04772092
Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions.
NCT05138666
Association of Neutrophil- Lymphocyte Count Ratio and Microbial Infection in Hospitalized Patients
NCT06759662
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In case of multiple stays over the study period, only the last one was included in the analysis.
In total, over this 12-month period, we analyzed the stays of patients affected by 126 father codes (entitled "family" of pathology) which were sometimes broken down into child codes (pathologies corresponding to these groups).
The database had been declared to the French Authority for Data Protection (Commission Nationale de l'Informatique et des Libertés - CNIL) via the Assistance Publique - Hôpitaux de Paris (AP-HP) (whose registration number is the 2216836).
Data were collected retrospectively by a single investigator, from the patient's medical record on Agfa® Orbis software. The same software made it possible to consult the totality of the biology, the images as well as the treatments administered throughout the stay.
In this study, eosinopenia is defined by an eosinophil count under 100 eosinophils/mm3 based on our previous studies.
Considering D0 as the date of the start of diagnosis by a clinician in the hospital, the other four dates were between D1 and D7.
The patients were separated into two groups: a group of patients who died during hospitalization and a group of patients released alive from their stay. If the patients were still hospitalized 30 days after their admission, they were classified in the group of "living" patients since they had not died on D30.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Survivors
Patients admitted in geriatrics that survived of a bacterial infection after 30 days (still admitted or discharged), and treated by antibiotics.
Eosinophil count
Evaluation of the eosinophil count from admission to day 7
Death
Deceased individuals admitted for a bacterial infection in geriatrics, despite receiving an antimicrobial therapy.
Eosinophil count
Evaluation of the eosinophil count from admission to day 7
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eosinophil count
Evaluation of the eosinophil count from admission to day 7
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infections of interest were pulmonary, urinary, digestive, biliary, cutaneous, cardiac, and central nervous system infections, as well as bacteremia.
* A White blood count cell with eosinophil count available at day 0 from admission, day 3 +/-1 day
Exclusion Criteria
* Disease that could influence the eosinophil count or that could be the cause of diagnostic errors:
* Acquired immunosuppression: HIV associated with a CD4 count of less than 200/mm\^3, immunosuppressive treatments (corticosteroid therapy at a dose ≥10 mg/d prednisone equivalent, anti-cancer chemotherapy, methotrexate etc.)
* Previous known haematological disorders
* Discrepancies between the hospital coding of International Classification of Diseases (ICD-10) and the diagnosis of bacterial infection into the medical chart • Patients already on antibiotic therapy for more than 48 hours before the inclusion
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre d'Investigation Clinique et Technologique 805
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
BENJAMIN DAVIDO, MD
Role: PRINCIPAL_INVESTIGATOR
Hopital Raymond Poincaré
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benjamin Davido
Garches, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EOSINOLD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.